• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • News
  • Lifestyle
  • Wellness
  • Cuisine
  • Product Reviews
  • Subscribe
Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Emerald Media News Subscription
  • Print Magazines
  • 100+ Minority-Owned Companies to Support
  • No Pipe, No Problem
  • Blunt vs. Joint
  • The Cost of Cannabis in Each State
  • Calculating Your Edibles Dosage
  • Flintts Mouthwatering Mints

Strainprint™ Technologies, Lumir Lab and Gynica Announce Clinical Trial Partnership Establishing World’s First and Largest Database of Medical Cannabis Effects on Women

November 19, 2018 by Emerald Media Group Leave a Comment

This information was provided by strainprint.ca

Send your Press Release here.

Strainprint™ Technologies, Lumir Lab and Gynica Announce Clinical Trial Partnership

Establishing World’s First and Largest Database of Medical Cannabis Effects on Women

International Study Monitoring Real-time Cannabis Treatment for the Symptoms of Endometriosis Will Leverage Strainprint’s Comprehensive Research Platform

TORONTO, Nov. 15, 2018 /CNW/ – Strainprint™ Technologies Ltd., the leader in cannabis data and analytics, today announced a partnership with Israeli research leaders, Lumir Lab and Gynica to conduct the world’s first international clinical study on the use of cannabis to treat endometriosis. Endometriosis, a condition where tissue from the uterine lining migrates to other organs inside the body affects roughly 180 million women worldwide. It is estimated that 1 in 10 women between the ages of 15 to 49 will be affected by symptoms of endometriosis during their lifetime.

Strainprint’s VP of Research, Michelle Arbus, will work closely with world-renowned cannabis scientist, Professor Lumir Hanus, along with Gynica’s Professor Moshe Hod, President of the European Association of Perinatal Medicine and Professor of Obstetrics and Gynecology at Tel Aviv University medical school. The intention of the study is to develop clinically-validated cannabinoid-based products that can be approved for international distribution. Gynica holds a federal license by the Israeli Ministry of Health to research the effects of cannabinoids on women’s health and gynecological disorders.

“Endometriosis remains one of the most misdiagnosed and least understood medical conditions, and currently, there is no cure,” said Professor Hod. “Strainprint’s early observational studies show that medical cannabis treatment has a positive effect on symptoms related to endometriosis, but much more research is required. Our objective is to identify which active cannabinoids, terpenes, and flavonoids, in relative combination, provide the most effective relief, reduce pain and prevent reoccurrence.”

Simultaneous studies in both Israel and Canada will leverage Strainprint’s research-ready platform to provide ethics approval, validated questionnaires, custom surveys, real-time treatment tracking and data visualization in support of in-clinic visits. Gynica Senior scientist, Dr. Sari Prutchi Sagiv, will develop the joint-study protocol to be used for clinical trial applications in both countries, based on a common product formulation. Drawing first from Strainprint’s 900,000+ real-time patient outcomes and 40 million medical cannabis data points, Lumir Lab will narrow and validate a formulation to focus on at the study. Together, the parties will use Strainprint’s recently launched community portal to recruit up to 1,000 patients in each country.

Dr. Prutchi Sagiv says “The combination of Strainprint’s big data analytics combined with Gynica’s scientific team and clinical research capabilities create a unique and innovative approach for providing evidence-based products to patients worldwide, and moreover for women who are under-treated by current solutions.”

Gynica, Lumir Lab and Strainprint expect the clinical study to run on Q2 of 2019.

“It’s truly amazing for all of us at Strainprint to get to work with this team of world-renowned scientists and doctors on such a significant medical issue,” said Strainprint CEO, Andrew Muroff. “We’re committed to helping improve the lives of millions of women suffering from endometriosis.”

Filed Under: Press Release Tagged With: Press

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Subscribe to Emerald's Newsletter

loader

Advertise Here

Categories

Sustainability

seaweed naturals

SeaWeed Naturals Combines the Power of Seaweed with Cannabis to Further Ocean Restoration

April 3, 2022 By Maggie Horton

fungi climate change

Research Finds Fungi Help Ease Climate Change and Benefit the Environment

March 30, 2022 By Julia Meyer

climate crisis and the pandemic

“We Can Act:” What Bending the COVID-19 Curve Teaches Us About the Climate Crisis

April 21, 2020 By Melissa Hutsell

Footer

  • Subscribe
  • About
  • Contact
  • Privacy
  • Press

Recent

  • Are Pre-Rolls the Future of Cannabis Retail?
  • Oxalis Integrative Support Services
  • Unlocking the Future of Cannabis Consumption: Amedicanna’s Nano Emulsified Beverages
  • From Veterans to Entrepreneurs: How Emanuel Ledezma, Rudy Rendon, and Erwin Sibal Became Leaders in the Cannabis Industry 
  • Cannifest 2023

Search

Copyright © 2023 · The Emerald™ · News & Lifestyle Magazine

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Cannabis News and Culture Magazine
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.